4basebio PLC announced a Joint Development Agreement with Heqet Therapeutics S.r.l. This JDA is focussed on the development of a non-viral vector, incorporating a proprietary Heqet payload for cardiomyocyte regeneration and treatment of myocardial infarction more broadly. Under the JDA, the companies will evaluate the use of 4basebio's Hermes non-viral nanoparticle for the delivery of payloads targeting cardiomyocyte regeneration. The successful outcome of this project may lead to the proof-of-concept development of a therapy enabling heart regeneration post infarction.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,220 GBX | +5.17% | +12.96% | +79.41% |
04-10 | 4basebio to supply synthetic DNA for mRNA vaccine program | AN |
04-10 | 4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.41% | 196M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+46.00% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- 4BB Stock
- News 4basebio PLC
- 4basebio PLC Announces Joint Development Agreement with Heqet Therapeutics